Recombinant Human Beta-galactoside alpha-2,6-sialyltransferase 1 (ST6GAL1)

Code CSB-CF022759HU
Size $1620
Order now
Image
  • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.

Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity
Greater than 85% as determined by SDS-PAGE.
Target Names
ST6GAL1
Uniprot No.
Research Area
Immunology
Alternative Names
ST6GAL1; SIAT1; Beta-galactoside alpha-2,6-sialyltransferase 1; Alpha 2,6-ST 1; B-cell antigen CD75; CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,6-sialyltransferase 1; ST6Gal I; ST6GalI; Sialyltransferase 1
Species
Homo sapiens (Human)
Source
in vitro E.coli expression system
Expression Region
1-406aa
Target Protein Sequence
MIHTNLKKKFSCCVLVFLLFAVICVWKEKKKGSYYDSFKLQTKEFQVLKSLGKLAMGSDSQSVSSSSTQDPHRGRQTLGSLRGLAKAKPEASFQVWNKDSSSKNLIPRLQKIWKNYLSMNKYKVSYKGPGPGIKFSAEALRCHLRDHVNVSMVEVTDFPFNTSEWEGYLPKESIRTKAGPWGRCAVVSSAGSLKSSQLGREIDDHDAVLRFNGAPTANFQQDVGTKTTIRLMNSQLVTTEKRFLKDSLYNEGILIVWDPSVYHSDIPKWYQNPDYNFFNNYKTYRKLHPNQPFYILKPQMPWELWDILQEISPEEIQPNPPSSGMLGIIIMMTLCDQVDIYEFLPSKRKTDVCYYYQKFFDSACTMGAYHPLLYEKNLVKHLNQGTDEDIYLLGKATLPGFRTIHC
Note: The complete sequence including tag sequence, target protein sequence and linker sequence could be provided upon request.
Mol. Weight
52.1kDa
Protein Length
Full Length
Tag Info
N-terminal 6xHis-tagged
Form
Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer
If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting and FAQs
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time
Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA
Please contact us to get it.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Transfers sialic acid from CMP-sialic acid to galactose-containing acceptor substrates.
Gene References into Functions
  1. Although ST6GalI overexpression increased HER2 sialylation, corresponding to decreased HER2 phosphorylation, high alpha2,6sialylation enhanced Akt and ERK phosphorylation levels compared to those in the vector cell line; ST6GalI knockdown had the opposite effects. Collectively, these results implicated a functional role of ST6GalI in promoting tumor cell progression and trastuzumab resistance. PMID: 30226606
  2. cells grown in hypoxia for several weeks displayed enriched ST6Gal-I expression, consistent with a pro-survival function. Taken together, these findings unravel a glycosylation-dependent mechanism that facilitates tumor cell adaptation to a hypoxic milieu. PMID: 29475939
  3. by restraining TNFR1 at the cell surface via sialylation, ST6Gal-I acts as a functional switch to divert signaling toward survival. These collective findings point to a novel glycosylation-dependent mechanism that regulates the cellular response to TNF and may promote cancer cell survival within TNF-rich tumor microenvironments. PMID: 29233887
  4. ST6GAL1 might be a potential target for atherosclerosis prevention and treatment. PMID: 29654763
  5. We discovered three significant associations at rs6679677 on 1p13.2 (P=6.15x10-5, OR=5.07), rs16861329 on 3q27.3 (P=2.02x10-4, OR=0.87) and rs849135 on 7p15.1 (P=6.59x10-9, OR=1.78), which suggested PTPN22, ST6GAL1 and JAZF1 as novel susceptibility genes for psoriasis in Chinese population. PMID: 28603863
  6. Suggest a crucial role for ST6Gal1 in elevating the invasiveness of pancreatic ductal adenocarcinoma cells in a fructose-responsive manner. PMID: 28032597
  7. these results indicate that ST6Gal-I plays a critical role in cell proliferation and invasion via the PI3K/Akt/GSK-3beta/beta-catenin signaling pathway during cancer progression PMID: 27588482
  8. these results indicate that ST6Gal-I might play a positive role in mediating the survival of human hepatocarcinoma cells PMID: 27340870
  9. The results demonstrate that epigenetic modulation of ST6Gal1 expression plays a key role in the glioma phenotype in vitro and that that therapeutic approaches targeting elements of the epigenetic machinery for the treatment of human glioblastoma are warranted. PMID: 27510958
  10. The data confirm that circulatory ST6Gal-1 is a negative systemic regulator of granulopoiesis PMID: 28550122
  11. Results provide evidence that ST6GAL1 contributes to drug resistance in cervical neoplasm. PMID: 27986075
  12. High ST6GAL1 expression is associated with ovarian and pancreatic Cancers. PMID: 27216178
  13. ST3Gal I and ST6Gal I have different sialic acid donor specificity. PMID: 28395125
  14. Taken together, these results indicate a dynamic change in the expression of ST6GAL1 during the CRC progression and provide a list of sialylated proteins potentially relevant to the different functions of ST6GAL1 in CRC. PMID: 28377225
  15. The results presented in this study provide an important advance by highlighting a new function for ST6Gal-I in promoting the viability of tumor cells exposed to the type of serum-depleted conditions often found in hypovascularized tumor microenvironments. PMID: 28154177
  16. High ST6GAL1 expression is associated with aging. PMID: 26840264
  17. Collectively, our data indicate that ST6GAL1 plays an important role in the regulation of pluripotency and differentiation in hPSCs. PMID: 26304831
  18. These results suggest a role for ST6Gal-I to promote the growth and invasion of osteosarcoma cells. PMID: 26054692
  19. Data indicate that O-glycan-specific alpha2,6 sialyltransferase regulate cancer growth and metastasis by regulating galectins Gal-1- and Gal-3-binding moieties on O-glycans. PMID: 26224120
  20. Expression levels of sialyltransferases ST3GAL1 and ST3GAL4 were upregulated in the HRMECs after high-glucose stimulation. PMID: 26258617
  21. Sialylation by beta-galactoside alpha-2,6-sialyltransferase regulates cell adhesion and invasion in human anaplastic large cell lymphoma. PMID: 25573487
  22. CDX2 transcriptionally regulates ST6GalNAc-I gene expression, specifically in the preneoplastic intestinal metaplasia lesion. PMID: 25867765
  23. Study characterizes ST6GAL1 expression loss caused by aberrant ST6GAL1 promoter methylation potentially indicating a tumor suppressive role in bladder carcinogenesis. PMID: 25465919
  24. ST6GAL1 promotes TGF-beta-dependent epithelial-mesenchymal transition PMID: 25344606
  25. The lymphocyte levels of NEU1 and ST6GAL1 mRNA expression are significantly increased in erythremia. PMID: 25566667
  26. The study detected only one allele of each polymorphism in the ST6GAL1P1 promoter. PMID: 24606438
  27. ST6GAL1 is responsible for the development of multidrug resistance in human leukemia cells probably through medicating the activity of PI3K/Akt signaling. PMID: 24454800
  28. A large glycan from a symmetry mate localizes to the active site of ST6Gal-I in an orientation compatible with catalysis. The glycan binding mode can be generalized to any glycoprotein that is a substrate of ST6Gal-I. PMID: 23999306
  29. the high expression of ST3Gal I and ST6Gal I, in skin tumors, is associated with tumors with greater potential for invasion and metastasis, as in the case of squamous cell carcinoma, and this may be related to their behavior. PMID: 23549466
  30. ST6Gal-I protein expression is upregulated in epithelial tumors. PMID: 23358684
  31. the suppressive role of Necl-2 in the HRG-induced ErbB2/ErbB3 signaling is regulated by miR-199a at least through the reduction of the ST6GAL1-catalyzed sialylation of Necl-2 PMID: 23504322
  32. These results indicated that gastric cancer tissues expressed high levels of alpha 2,3-linked sialic acid residues, ST3Gal IV, and ST6Gal I. PMID: 21140242
  33. Our results suggest that soluble ST6Gal may participate in cancer progression and metastasis prior to being secreted from cancer cells PMID: 22449099
  34. ST6Gal-I regulates macrophage apoptosis via alpha2-6 sialylation of the TNFR1 death receptor. PMID: 21930713
  35. CDw75 expression in colorectal tumoural tissue was correlated with growth pattern (p = 0.044), Dukes stage (p = 0.002), TNM stage (p = 0.020) and distant metastasis (p = 0.005). PMID: 21778787
  36. the occurrence of CD75s- and iso-CD75s-gangliosides in tumor tissues is largely independent of the transcriptional expression of ST6GAL1 and ST3GAL6 PMID: 21147760
  37. Sialylation of the Fas death receptor by ST6Gal-I provides protection against Fas-mediated apoptosis in colon carcinoma cells. PMID: 21550977
  38. ST6Gal I is responsible for ST2H antigen biosynthesis in human colon cancer cells. PMID: 20656882
  39. siRNA targeting to ST6Gal I can effectively downregulate the ST6Gal I expression in HeLa cell and further lead to the decline of cell adhesion and invasiveness to ECM. PMID: 17441333
  40. ST6Gal I and ST3Gal V were positively correlated with the high risk of pediatric acute leukemia. PMID: 19709745
  41. enhanced tumour ST6Gal I activity and an increased CDw75 expression may play a role in malignant transformation of colorectal cancer PMID: 20003255
  42. ST6Gal I sialyltransferase has a role in regulating galectin-1-induced CD45 clustering, phosphatase modulation, and T cell death PMID: 12499376
  43. Expression of alpha 2,6-sialyltransferase ST6Gal I is enhanced in cervical squamous cell carcinoma. PMID: 12798701
  44. Transcriptional activation of beta-galactoside alpha2,6-sialyltransferase in colon adenocarcinoma cells. PMID: 12878221
  45. High levels of ST6GAL-I in the tumor tissue correlated with secondary local tumor recurrence (p = 0.005; p = 0.012). PMID: 12931020
  46. specific kinase enzymes have important roles in the expression and catalytic activity of the alpha2,6 STN (ST6N) isozyme PMID: 12943659
  47. Neoplastic transformation but not cirrhosis can alter the process of alpha2,6-sialylation of liver glycoproteins. PMID: 14514712
  48. sialyltransferases expression and activity are increased in Grave's disease PMID: 16053379
  49. the presence of alpha2,6-linked sialic acid added by ST6Gal.I on membrane glycoconjugates increases the binding to extracellular matrix components, resulting in a membrane stabilization of beta1 integrins, further strengthening the binding PMID: 16192407
  50. ST6Gal I is upregulated in tumor and transitional tissues from colorectal cancer patients PMID: 16319516

Show More

Hide All

Subcellular Location
Golgi apparatus, Golgi stack membrane; Single-pass type II membrane protein. Secreted. Note=Membrane-bound form in trans cisternae of Golgi. Secreted into the body fluid.
Protein Families
Glycosyltransferase 29 family
Database Links

HGNC: 10860

OMIM: 109675

KEGG: hsa:6480

STRING: 9606.ENSP00000169298

UniGene: Hs.207459

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*